The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

Tris Pharma’s opioid alternative has scored a third win in a trio of clinical trials, providing the biotech with the data ...

Researchers have developed a compound that relieves pain in mice but doesn't affect the brain, thereby avoiding mind-altering side effects and abuse potential. The custom-designed molecule, derived ...

A scientific statement regarding pain and treatment considerations in patients with PAD has been published by the AHA.

The case was recently the focus of a five-part, Peabody award-winning New York Times Podcast, "The Retrievals," written and ...

Vertex Pharmaceuticals secured a Buy rating from Leerink Partners analyst David Risinger. The firm’s newly approved pain ...

In two randomized clinical trials evaluating pain control following abdominoplasty and bunionectomy, Journavx demonstrated ...

Ditch the painkillers! While they can provide temporary relief, there are other ways to numb pain without medication. Find ...

“I believe JOURNAVX could redefine the management of pain and become a foundational treatment option for people with all types of moderate-to-severe acute pain, where options aside from opioids ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

The U.S. Food and Drug Administration (FDA) has approved Journavx, the first opioid-free prescription drug for moderate to ...